5-FU AND CERVICAL CA

被引：0

作者：

TRELFORD, JD ^{[1
]}

机构：

[1] UNIV CALIF,DEPT OBSTET & GYNECOL,DAVIS,CA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

下载

页码：151 / 151

页数：1

共 50 条

[31] Predicting the response to 5-FU chemotherapy
Cannell, E
EUROPEAN JOURNAL OF CANCER, 2004, 40 (01) : 2 - 2
[32] 5-FU TOXICITY AND NUTRITIONAL DEFICIENCIES
STENRAM, U
BRITISH JOURNAL OF CANCER, 1993, 67 (05) : 1157 - 1157
[33] MORE ON TREATING KERATOSES WITH 5-FU
DANA, WJ
DRUG THERAPY, 1974, 4 (05) : 19 - 20
[34] Capecitabin replaces 5-FU in radiochemotherapy
不详
STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 (09) : A3 - A3
[35] Acute encephalopathy attributed to 5-FU
Langer, CJ
Hageboutros, A
Kloth, DD
Roby, D
Shaer, AH
PHARMACOTHERAPY, 1996, 16 (02): : 311 - 313
[36] Oral 5-FU and digestive cancers
Taïeb, J
Desramé, J
Artru, P
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2003, 28 (03): : 231 - 239
[37] Hepatotoxicity of 5-FU: a case report
Sternfeld, T.
Greif, D.
Kaeser, F.
Vehling-Kaiser, U.
ONKOLOGIE, 2010, 33 : 67 - 67
[38] Clinical implications of 5-FU modulation
Rustum, YM
ONCOLOGY-NEW YORK, 1999, 13 (07): : 22 - 25
[39] Fluorouracil (5-FU)-induced Cardiomyopathy
Thalambedu, Nishanth
Khan, Yasir
CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (07)
[40] Feasibility of 5-FU therapeutic monitoring
Coudert, B
deGislain, C
Beltramo
Riedinger, JM
Mayer, F
Bruchon, FY
Dumas, M
Fargeot, P
Guerrin, J
EUROPEAN JOURNAL OF CANCER, 1995, 31A : 966 - 966